John Iwanicki

The USPTO Announces New Guidelines For Determining Subject Matter Eligibility Under 35 U.S.C. §101 In View Of "Myriad", "Prometheus" And "Chakrabarty"

The Biosimilars Act: The United States’ Entry Into Regulating Biosimilars And Its Implications